Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats

Eur J Pharmacol. 2012 Feb 15;676(1-3):89-94. doi: 10.1016/j.ejphar.2011.11.051. Epub 2011 Dec 8.

Abstract

The study was designed to investigate the antihyperglycemic effect of biochanin A on streptozotocin-diabetic rats. Diabetes was induced in adult male albino rats of the Wistar strain, weighing 180-200 g, by administration of streptozotocin (40 mg/kg of body weight) intraperitoneally. Diabetic rats showed increase in plasma glucose and glycosylated hemoglobin and a decrease in plasma insulin and hemoglobin. Activities of gluconeogenic enzymes such as glucose 6-phosphatase, fructose 1,6-bisphosphatase increased and glucokinase, glucose 6-phosphate dehydrogenase decreased in the liver of diabetic rats along with glycogen. Oral administration of biochanin A (10mg/kg body weight) or glibenclamide (600 μg/kg body weight) in 0.5% dimethyl sulfoxide, for 45 days, prevented the above changes and improved towards normality. In addition, protection against body weight loss of diabetic animals by biochanin A was also observed. No significant effect was observed in normal rats treated with biochanin A (10mg/kg bodyweight). These results showed that biochanin A has potential antihyperglycemic activity at a dose of 10mg/kg bodyweight in streptozotocin induced diabetic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / metabolism
  • Body Weight / drug effects
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / enzymology
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / pathology
  • Genistein / pharmacology*
  • Genistein / therapeutic use
  • Gluconeogenesis / drug effects
  • Glycine max / chemistry*
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Rats

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Genistein
  • biochanin A